Heptares doses first subject in Alzheimer’s drug trial
Heptares | September 01, 2017
London, UK-based Heptares Therapeutics says the first healthy subject has now been dosed with its first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase I clinical study. The move triggers a $15 million milestone payment from Allergan under a global R&D and commercialization partnership signed in April last year, under which Allergan licensed exclusive global rights to Heptares’ broad portfolio of novel subtype-selective muscarinic receptor agonists for the treatment of major neurological disorders.